Our group also demonstrated that heavily pretreated metastatic BC patients who were found to display MET mutations or amplifications had frequent high-grade histology, higher metastatic disease burden, and inferior outcomes during phase I clinical trials[14]. The gene discussed is MET; the disease is breast cancer.